Dr. Jörg C. Mahlich

Düsseldorf Institute for Competition Economics (DICE)
Heinrich-Heine-Universität Düsseldorf
Universitätsstr. 1
40225 Düsseldorf

Positionen
Seit 2017	Janssen (Johnson & Johnson), Neuss
2014 - 2017	Janssen (Johnson & Johnson), Tokyo, JP
2010 - 2014	Janssen (Johnson & Johnson), Neuss
2004 - 2010	Wirtschaftskammer Österreich, Wien
2001 - 2003	Technopolis, Wien
2001	United Nations Development Organization, Wien
1998-2000	Austrian Institute of Technology, Seibersdorf
1997	Bayer Yakuhin, Osaka
1996-1997	Deutsche Industrie- und Handelskammer, Osaka

Repräsentative Veröffentlichungen
Zeidler J, Mahlich J, Greiner W, Heres, S (2013) Cost-Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany, Applied Health Economics and Health Policy 11(5), 509-521. Dimai HP, Redlich K, Peretz M, Borgström F, Siebert U, Mahlich J (2012) Economic Burden of Osteoporotic Fractures in Austria, Health Economics Review, 2:12. Mahlich J (2010) Patents and Performance in the Japanese Pharmaceutical Industry: an Institution-Based View, Asia Pacific Journal of Management, 27 (1), 99-113. Mahlich J (2007) The Japanese Pharmaceutical Industry in Transition: Has Higher Research Orientation Resulted in Higher Market Value?, Asian Business & Management, 6 (1), 75-94. Mahlich J, Roediger-Schluga T (2006) Determinants of Pharmaceutical R&D: Evidence from Japan, Review of Industrial Organization, 28 (2), 145-164.

Repräsentative Veröffentlichungen

Zeidler J, Mahlich J, Greiner W, Heres, S (2013) Cost-Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany, Applied Health Economics and Health Policy 11(5), 509-521.
Dimai HP, Redlich K, Peretz M, Borgström F, Siebert U, Mahlich J (2012) Economic Burden of Osteoporotic Fractures in Austria, Health Economics Review, 2:12.
Mahlich J (2010) Patents and Performance in the Japanese Pharmaceutical Industry: an Institution-Based View, Asia Pacific Journal of Management, 27 (1), 99-113.
Mahlich J (2007) The Japanese Pharmaceutical Industry in Transition: Has Higher Research Orientation Resulted in Higher Market Value?, Asian Business & Management, 6 (1), 75-94.
Mahlich J, Roediger-Schluga T (2006) Determinants of Pharmaceutical R&D: Evidence from Japan, Review of Industrial Organization, 28 (2), 145-164.

Verantwortlichkeit: